Recent IBRX Stock Price | IBRX Stock Predictions | |
$8.54 | -12.18% |
$7.50 |
Recent IBRX Analyst Ratings Breakdown, Making IBRX Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 1 | 1 | 1 | 1 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 1 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 2.0 | 2.0 | 2.0 | 2.0 |
For the IBRX stock predictions from the analysts covering ImmunityBio Inc, we have collected all of the individual IBRX stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 2 different analysts covering IBRX (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since IBRX stock predictions may vary widely, another useful metric to consider is the median IBRX stock prediction, which represents the price at which half of the analysts
made IBRX stock predictions that were higher and half made IBRX stock predictions that were lower. This makes for a different take on the IBRX stock predictions out there, as compared to average or mean.
And that median across all the individual IBRX stock predictions was: $7.5 as of 2024-05-02.
The very highest of the IBRX stock predictions for one year price target was $9.0, while the very lowest of the IBRX stock predictions in the analyst group was
$6.0 (with a standard deviation of $2.121). Get the latest Zacks research report on IBRX — FREE
Find out: IBRX next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
DISCA Stock Predictions
MPWR Stock Predictions
MDU Stock Predictions
ANGI Stock Predictions
EPC Stock Predictions
FCFS Stock Predictions
RYAM Stock Predictions
LSXMK Stock Predictions
APAM Stock Predictions
|
|
Buy (3.00 out of 4) 34th percentile
(ranked lower than approx. 66% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |